| abstract |
The present invention is selective for purinergic (P2X) receptors, more specifically P2X7 receptors, antibody production, and non-ATP binding P2X7 receptors for the detection and treatment of disease states, particularly cancer. Relates to the use of antibodies and immunogens that are capable of binding to but not capable of binding to the ATP-binding P2X7 receptor. |